NasdaqCM - Nasdaq Real Time Price USD

Cyclacel Pharmaceuticals, Inc. (CYCC)

0.2302

+0.0046

+(2.04%)

At close: April 23 at 4:00:00 PM EDT

0.2300

-0.00

(-0.09%)

After hours: April 23 at 7:46:22 PM EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. “As part of Cyclacel’s efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematologic

GlobeNewswire 21 days ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series E Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $1.0 million before deducting offering expenses. The offering cl

GlobeNewswire 30 days ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025. Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on Febru

GlobeNewswire last month

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO

Cyclacel Pharmaceuticals (CYCC) said investor David Lazar agreed to buy $3.1 million in preferred st

PREMIUM
MT Newswires 3 months ago

CYCC
+2.04%
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEOBERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced that the Company entered into a securities purchase agreement (“Agreement”) with investor David Lazar (“Lazar”), pursuant to which he agreed to purchase from the Company 1,000,000 shares of Series C Convertible Preferred Stock (the “C Preferred Stock”)

GlobeNewswire 3 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to th

GlobeNewswire 4 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Cyclacel Pharmaceuticals ( NASDAQ:CYCC ) Third Quarter 2024 Results Key Financial Results Net loss: US$1.96m (loss...

Simply Wall St. 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced

GlobeNewswire 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise p

GlobeNewswire 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 66.67% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CYCC
+2.04%
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. “We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a sing

GlobeNewswire 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq’s minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1) (th

GlobeNewswire 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities -BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 cli

GlobeNewswire 5 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalitiesBERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part o

GlobeNewswire 6 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

- Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 of its Phase 2 stage, proof of co

GlobeNewswire 6 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. The in-person venue for the event is the Lotte New York Palace Hotel in New York

GlobeNewswire 7 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Delisting or suspension action stayed pending the issuance of a final decisionBERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) and a hearing has been scheduled for October, 15, 2024. The request automat

GlobeNewswire 7 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cyclacel Pharmaceuticals (CYCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 7 months ago

CYCC
+2.04%
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cyclacel Pharmaceuticals ( NASDAQ:CYCC ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.26m (loss...

Simply Wall St. 8 months ago

CYCC
+2.04%
CYCCP
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates

Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 13.25% and 86.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 8 months ago

CYCC
+2.04%

Performance Overview

Return	CYCC	S&P 500 (^GSPC)
YTD	-39.42%	-8.60%
1-Year	-87.14%	+6.02%
3-Year	-99.21%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Cyclacel Pharmaceuticals Says David Lazar Buys $3.1 Million in Preferred Stock, Becomes Interim CEO

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates

Performance Overview